Achillion Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Achillion Pharmaceuticals.

Results 1 - 20 of 146 in Achillion Pharmaceuticals

  1. Traders Brace for an Achillion Pharmaceuticals, Inc. (ACHN) SlideRead the original story

    Monday Jul 14 | SchaeffersResearch.com

    ... forfeit, should the stock be sitting above the strike at the end of the week. On the charts, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has given back a portion of Friday's gains, down 1.6% out of the gate to trade at $7.52. However, the shares ...

    Comment?

  2. Achillion Pharmaceuticals, Inc. Added To The Russell 2000 And Russell Microcap IndexesRead the original story

    Wednesday Jul 2 | BioSpace

    Achillion Pharmaceuticals, Inc. announced that it has been added to the Russell 2000 and Russell Microcap Indexes.

    Comment?

  3. Bayer plans to keep Coppertone, Dr. Scholl's from Merck, Reuters saysRead the original story

    Jun 17, 2014 | Theflyonthewall.com

    ... per share in cash, which was subsequently accepted and announced on June 9. Shares of Idenix peer Achillion Pharmaceuticals (ACHN) are up 4.7% to $8.46 in early trading following the disclosure that a bidder other than Merck had previously offered ...

    Comment?

  4. Achillion Pharmaceuticals Sees Large Increase in Short InterestRead the original story

    Monday Jun 30 | AmericanBankingNews.com

    Shares of Achillion Pharmaceuticals were the target of a large growth in short interest in the month of June.

    Comment?

  5. Merck's pembrolizumab under regulatory review in EuropeRead the original story

    Jun 17, 2014 | Theflyonthewall.com

    ... per share in cash, which was subsequently accepted and announced on June 9. Shares of Idenix peer Achillion Pharmaceuticals (ACHN) are up 4.7% to $8.46 in early trading following the disclosure that a bidder other than Merck had previously offered ...

    Comment?

  6. Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay LulyRead the original story w/Photo

    Friday Jun 27 | Benzinga

    Merck paid a 230 percent premium for Hepatitis C-focused Idenix Pharmaceuticals .

    Comment?

  7. RA Capital Management Sells 800,000 Shares of Achillion Pharmaceuticals Inc.Read the original story w/Photo

    Wednesday Jun 25 | Insider Monkey

    ACHN ) in two transactions for about $8 apiece on June 20, 2014. Following the sale, the fund currently owns around 22.49 million shares, down from 23.37 million shares disclosed previously, according to a new filing with the U.S. Securities and Exchange Commission.

    Comment?

  8. Achillion Pharmaceuticals Insider Sells $7,392,000 in StockRead the original story

    Jun 24, 2014 | AmericanBankingNews.com

    Achillion Pharmaceuticals Insider Ra Capital Management, Llc sold 880,000 shares of the company's stock on the open market in a transaction that occurred on Friday, June 20th.

    Comment?

  9. Ibd TVRead the original story

    Jun 19, 2014 | Investor's Business Daily

    ... today Friday, after the casual-dining eatery served up a double-digit decli... Hot biotech stock Achillion Pharmaceuticals was up 2%, near 8.20, in midday trading in the stock market today after an analyst found more support for ... Kite Pharma ...

    Comment?

  10. Options with decreasing implied volatilityRead the original story

    Jun 6, 2014 | Theflyonthewall.com

    ... and Idenix shares rose more than 230% to trade near $24.09 after the announcement. Shares of Achillion Pharmaceuticals (ACHN), which has developed its own HCV drugs, were up 40% as investors speculate it could be the next takeover target in the ...

    Comment?

  11. Merck begins tender offer to acquire IdenixRead the original story

    Jun 6, 2014 | Theflyonthewall.com

    ... and Idenix shares rose more than 230% to trade near $24.09 after the announcement. Shares of Achillion Pharmaceuticals (ACHN), which has developed its own HCV drugs, were up 40% as investors speculate it could be the next takeover target in the ...

    Comment?

  12. Achillion Pharmaceuticals major shareholder Qvt Associates Gp Llc Unloads 1,819,551 SharesRead the original story

    Jun 18, 2014 | AmericanBankingNews.com

    Achillion Pharmaceuticals major shareholder Qvt Associates Gp Llc sold 1,819,551 shares of the stock on the open market in a transaction that occurred on Monday, June 16th.

    Comment?

  13. Analyst: In Merck-Idenix deal, 'biggest question' is why Gilead wasn't the suitorRead the original story w/Photo

    Jun 18, 2014 | Business Journal

    ... A few other companies have a "nuke" in development, said Levine-Wilkinson, including Roche and Achillion Pharmaceuticals. But the fact is that Gilead, with the first such drug to reach market, is likely to rule the disease space for some time to ...

    Comment?

  14. Insider Selling: Achillion Pharmaceuticals EVP Sells 25,000 Shares of StockRead the original story

    Jun 17, 2014 | AmericanBankingNews.com

    Achillion Pharmaceuticals EVP Joseph Truitt sold 25,000 shares of Achillion Pharmaceuticals stock on the open market in a transaction that occurred on Monday, June 16th.

    Comment?

  15. Insider Selling: Achillion Pharmaceuticals Director Unloads 55,000 Shares of StockRead the original story

    Jun 17, 2014 | AmericanBankingNews.com

    Achillion Pharmaceuticals Director Gary E. Frashier unloaded 55,000 shares of the stock on the open market in a transaction that occurred on Monday, June 16th.

    Comment?

  16. Hepatitis C May Give A Big Boost To These Drug Stocks - If The FDA ApprovesRead the original story

    Jun 17, 2014 | Seeking Alpha

    ... big name firms, as well as smaller biotechs like Conatus Pharmaceuticals ( CNAT ) and Achillion Pharmaceuticals ( ACHN ). DuPont analysis reveals that Bristol-Myers Squibb ( BMY ) has better sources of profitability than other companies currently ...

    Comment?

  17. Achillion Gets Massive Price Target Hike On HCV DrugsRead the original story

    Jun 16, 2014 | Investor's Business Daily

    After having dinner with company executives, analyst Jason Kolbert hiked his target to 22 from 6, while maintaining his buy rating.

    Comment?

  18. Traders Buy High Volume of Call Options on Achillion PharmaceuticalsRead the original story

    Jun 16, 2014 | AmericanBankingNews.com

    Achillion Pharmaceuticals was the target of unusually large options trading on Monday.

    Comment?

  19. Achillion Set to See Shares SoarRead the original story

    Jun 16, 2014 | Barron's

    Our valuation is based on our assumptions for the commercialization of an Achillion (ticker: ACHN) single-tablet regimen (STR) (NS5A/NS5B/PI) in Hepatitis C virus (HCV). We use a 30% discount rate in our free-cash-flow model to derive a $22.00 price target. Our...

    Comment?

  20. Why Fusion-io, Achillion Pharmaceuticals, and Covidien Are Today's 3 Best StocksRead the original story w/Photo

    Jun 16, 2014 | The Motley Fool

    Following the first down week for the broad-based S&P 500 in quite some time investors were looking for something positive to start their work week, and a bevy of economic data gave them what they were looking for.

    Comment?